ArticleCureus2025
Drug-Induced Pancreatitis Caused by Mesalazine in an Adolescent Man With Ulcerative Colitis: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drugs are a rare cause of acute pancreatitis. Mesalazine, a medication used to treat inflammatory bowel disease (IBD), has been reported to cause drug-induced pancreatitis. Here, we report a case strongly suggestive of mesalazine-induced pancreatitis. A 20-year-old man presented with left upper abdominal pain after eating. He was diagnosed with acute pancreatitis based on clinical symptoms, elevated amylase levels, and findings from contrast-enhanced computed tomography. Notably, he had been diagnosed with ulcerative colitis (UC) and had started mesalazine therapy six months earlier. Mesalazine was strongly suspected as the causative agent and was subsequently discontinued. Other potential causes of pancreatitis, such as alcohol use and gallstones, were ruled out. The patient's condition steadily improved after discontinuing mesalazine, along with general supportive treatment for pancreatitis. No recurrence has been observed over several years since discontinuation. Although re-administration has not been attempted, the clinical course strongly supports mesalazine as the likely cause. When evaluating pancreatitis in patients receiving mesalazine, drug-induced pancreatitis should be considered a potential etiology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.